Trials / Completed
CompletedNCT03921411
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 Years) With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nemolizumab | Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1. |
Timeline
- Start date
- 2019-04-09
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2019-04-19
- Last updated
- 2023-04-21
- Results posted
- 2023-04-21
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03921411. Inclusion in this directory is not an endorsement.